Related Experiment Video
Updated: Sep 28, 2025
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease
Insights
Kawasaki disease treatment guidelines are updated. This consensus provides expert recommendations on using glucocorticoids (GC) for children with Kawasaki disease, addressing controversies in its first- and second-line treatment.
Area of Science:
- Pediatric Cardiology
- Rheumatology
- Immunology
Background:
- Kawasaki disease (KD) is a leading cause of acquired heart disease in young children.
- Intravenous immunoglobulin and aspirin are standard first-line KD treatments.
- Glucocorticoids (GC) are considered for high-risk KD patients but their use remains debated.
Purpose of the Study:
- To establish consensus-based recommendations for GC use in KD treatment.
- To clarify indications, dosage, and administration of GC in KD management.
- To address current controversies surrounding GC therapy in Kawasaki disease.
Main Methods:
- Review of latest international and domestic KD research findings.
- Expert panel discussion among leading pediatric specialists.
- Development of consensus recommendations on GC treatment protocols.
Main Results:
- Defined criteria for GC use in first-line and second-line KD therapy.
- Provided specific dosage and usage guidelines for GC in KD.
- Addressed controversies regarding GC efficacy and safety in KD.
Conclusions:
- GC can be a valuable therapeutic option in specific KD patient populations.
- Standardized GC protocols aim to optimize treatment outcomes and prevent coronary artery aneurysms.
- Further research may refine GC's role in Kawasaki disease management.
Abstract:
Kawasaki disease (KD) is one of the common acquired heart diseases in under-5-year-old children and is an acute self-limiting vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for preventing coronary artery aneurysm in the acute stage of KD. However, glucocorticoid (GC), infliximab, and other immunosuppressants are options for the treatment of KD patients with a high risk of coronary artery aneurysm, no response to intravenous immunoglobulin and a confirmed diagnosis of coronary artery aneurysm. At present, there are still controversies over the use of GC in the treatment of KD. With reference to the latest research findings of KD treatment in China and overseas, this consensus invited domestic pediatric experts to fully discuss and put forward recommendations on the indications, dosage, and usage of GC in the first-line and second-line treatment of KD.
Related Concept Videos
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:21Rheumatic Heart Disease III: Medical Management
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:14Myocarditis III: Medical Management
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes: